Transcatheter patent foramen ovale closure achieves high efficacy in migraine patients: a single-center retrospective cohort study in China - Scorecard - MDSpire
Advertisement
Transcatheter patent foramen ovale closure achieves high efficacy in migraine patients: a single-center retrospective cohort study in China
Clinical Scorecard: Efficacy of Transcatheter Closure of Patent Foramen Ovale in Migraine Patients: A Retrospective Cohort Analysis from a Single Center in China
At a Glance
Category
Detail
Condition
Migraine associated with Patent Foramen Ovale (PFO)
Key Mechanisms
Paradoxical embolism, shunting of vasoactive substances, hemodynamic alterations
Target Population
Chinese patients aged 15–65 years with moderate-to-large right-to-left shunt and HIT-6 score ≥60
Care Setting
Single-center, retrospective cohort study
Key Highlights
Overall migraine responder rate of 83.98%; 59.9% achieved complete/near-complete relief
Younger age (15–24 years) predicts better outcomes (89.67%) compared to older age groups
More recent procedure year independently predicts higher success rates
100% technical success rate with 3.49% minor complications and no major adverse events
Sustained therapeutic benefit after DAPT discontinuation (81.93% responder rate at >12 months)
Guideline-Based Recommendations
Diagnosis
Clinical diagnosis of migraine established by neurologists according to ICHD-3 criteria
Management
Transcatheter PFO closure for patients with moderate-to-large RLS and severe migraine
Monitoring & Follow-up
Follow-up assessments conducted between May 2024 and December 2024
Risks
Minor complications (3.49%) observed; no major adverse events reported
Patient & Prescribing Data
974 consecutive migraine patients aged 15–65 years
